ClinicalTrials.gg
CompletedNCT02682823Updated Apr 19, 2019Results posted

Tocilizumab Real-Life Human Factors (RLHFs) Validation Study

A Phase 4 interventional study of AI-1000 G2 and Tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-19.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Device feasibility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
91
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
58th of 110
91 · median 97
Started
2016
with 3 others
Phase 4
32 of 110
2 open now
Registered
91st of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 58th largest by enrollment, is one of 4 that started in 2016, is one of 32 in phase 4, and was the 91st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study is designed to evaluate RLHFs concerning administration of the tocilizumab autoinjector AI-1000 G2 in adults with rheumatoid arthritis (RA) who have been receiving subcutaneous (SC) tocilizumab using the commercially available prefilled syringe and needle safety device (PFS-NSD). The study will enroll participants with RA, a subset of whom will be assigned to perform self-injection with the AI-1000 G2. Enrolled caregivers (CGs) and healthcare professionals (HCPs) will administer the AI-1000 G2 injection to the remaining study participants.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with RA for greater than or equal to (>/=6) months receiving 162 mg tocilizumab PFS-NSD for >/=8 weeks and who are suitable for continued treatment at their currently prescribed dose
  • CGs and professionally qualified HCPs who are able and willing to administer the injection

Exclusion criteria

Exclusion Criteria:

  • RA: Functional status Class IV
  • RA: Neuropathies or other conditions that might interfere with pain evaluation
  • RA: Pregnant or breastfeeding
  • RA: Low neutrophil or count at last laboratory assessment
  • RA: Elevated liver enzymes at last laboratory assessment
  • Current participation in another interventional clinical trial
  • Criteria that might give the participant/CG/HCP an advantage in injection tasks such as employment in the pharmaceutical industry, etc.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Device feasibility
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Caregivers

    CGs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.

    Device: AI-1000 G2 · Drug: Tocilizumab

  • Experimental
    Healthcare Professionals

    HCPs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.

    Device: AI-1000 G2 · Drug: Tocilizumab

  • Experimental
    RA Group 1 (Self-Administration)

    Participants with RA will perform self-injection of SC tocilizumab with the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.

    Device: AI-1000 G2 · Drug: Tocilizumab

  • Other
    RA Group 2 (Administration by CG)

    CGs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.

    Device: AI-1000 G2 · Drug: Tocilizumab

  • Other
    RA Group 3 (Administration by HCP)

    HCPs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visit 1 (Day 0) will be performed by the study nurse. Visits 2 and 3 (Days 14 and 28) will be conducted by the HCP for use/performance evaluation.

    Device: AI-1000 G2 · Drug: Tocilizumab

Interventions

  • DeviceAI-1000 G2

    Tocilizumab will be administered using the AI-1000 G2.

  • Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28). The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.

    Also known as: Actemra/RoActemra, RO4877533

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During First Unassisted Use

    Safety-critical tasks included those tasks where errors would have a reasonably foreseeable potential for clinical impact/harm, potentially resulting in direct physical injury to the user and/or conditions that require medical intervention. Safety-critical tasks included the following: release activation button; check the expiry date; inspect device prior to use; and inspect medication prior to use. Essential tasks included those essential to the execution of the injection. Essential tasks included the following: open the carton, remove the device and associated documents; remove cap; start an injection by depressing the needle-shield at the injection site and pressing the activation button; and hold the autoinjector until the complete dose has been delivered. The percentage of participants who successfully performed safety-critical and essential tasks during the first unassisted use (Day 14) was reported.

    Time frame: Day 14

  2. Percentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During Second Unassisted Use

    Safety-critical tasks included those tasks where errors would have a reasonably foreseeable potential for clinical impact/harm, potentially resulting in direct physical injury to the user and/or conditions that require medical intervention. Safety-critical tasks included the following: release activation button; check the expiry date; inspect device prior to use; and inspect medication prior to use. Essential tasks included those essential to the execution of the injection. Essential tasks included the following: open the carton, remove the device and associated documents; remove cap; start an injection by depressing the needle-shield at the injection site and pressing the activation button; and hold the autoinjector until the complete dose has been delivered. The percentage of participants who successfully performed safety-critical and essential tasks during the second unassisted use (Day 28) was reported.

    Time frame: Day 28

Secondary outcomes

  1. Percentage of Participants Who Successfully Performed Ancillary Tasks During First and Second Unassisted Use

    Ancillary tasks included those tasks where the potential harm resulting from use error would be minor in severity, or the resultant harms were estimated to occur at sufficiently low levels. Ancillary tasks included the following: wash hands; clean the injection site with alcohol swab; wait for the alcohol to dry; dispose of the autoinjector cap; inspect full dose delivered after use; dispose of the autoinjector; and treatment of injection site after injection. The percentage of participants who succesffully performed ancillary tasks during the first (Day 14) and second unassisted use (Day 28) was reported.

    Time frame: Days 14, 28

  2. Visual Analog Scale (VAS) Score for Injection Pain Among Participants With RA

    Injection pain was assessed on a continuous 100-millimeter (mm) VAS, where 0 mm represents "no pain" and 100 mm represents "unbearable pain". The mean VAS response at each assessment timepoint was reported among participants with RA.

    Time frame: 0 and 15 minutes after injection on Days 0, 14, 28

  3. Percentage of Participants by Response to Categorical Scale of Injection Pain Among Participants With RA

    Injection pain was assessed on a categorical 6-point Likert scale, ranging from "no pain" to "severe and intolerable". The percentage of participants was reported by response at each assessment timepoint among participants with RA.

    Time frame: 0 and 15 minutes after injection on Days 0, 14, 28

  4. Percentage of Participants by Response to Device Satisfaction Questionnaire

    Device satisfaction was assessed using twelve questions on a categorical 5-point Likert scale, ranging from "strongly agree" to "strongly disagree". Question (Q) 1 (felt the autoinjection was easy to use), Q2 (felt comfortable while using the autoinjector), Q3 (felt the autoinjector was easy to hold), Q4 (able to tell when injection had completed), Q5 (felt he/she can inject properly with the autoinjector), Q6 (felt he/she had control over the injection process), Q7 (felt confident that he/she injected successfully), Q8 (felt it is easy to dispose of the autoinjector), Q9 (autoinjector would help to manage his/her injection schedule), Q10 (liked the look/feel of the autoinjector), Q11 (would recommend the autoinjector to someone else who needed to inject), Q12 (would continue having injections with the autoinjector). The percentage of participants was reported by response at each assessment among participants with RA, CGs, and HCPs.

    Time frame: Days 0, 14, 28

  5. Tender Joint Count (TJC) Among Participants With RA

    Sixty-eight joints were assessed for tenderness among participants with RA. The number of tender joints at Baseline was reported.

    Time frame: Baseline (Day 0)

  6. Swollen Joint Count (SJC) Among Participants With RA

    Sixty-six joints were assessed for swelling among participants with RA. The number of swollen joints at Baseline was reported.

    Time frame: Baseline (Day 0)

  7. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Among Participants With RA

    Ability to perform daily living activities was assessed across eight component sets including dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Twenty questions were scored on a 4-point Likert scale from 0 meaning "without any difficulty" to 3 meaning "unable to do". The overall score was computed as the sum of domain scores divided by the number of domains answered. Therefore, the score range for HAQ-DI was the same as that of the individual questions, that is, from 0 to 3, where 0 indicates "least difficulty" and 3 indicates "extreme difficulty". The mean change from baseline in HAQ-DI at each assessment was reported among participants with RA.

    Time frame: Days 0, 14, 28

07

Results

Posted Apr 19, 2019

Participant flow

Participant flow — Overall Study
MilestoneCaregiversHealthcare ProfessionalsRA Group 1 (Self-Administration)RA Group 2 (Administration by CG)RA Group 3 (Administration by HCP)
Started1719191719
Safety population1719181719
Completed1718181618
Not completed01111
Withdrew: Withdrawal by subject00101
Withdrew: Protocol deviation01000
Withdrew: Adverse event00010

Outcome measures

PrimaryPercentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During First Unassisted Use

Safety-critical tasks included those tasks where errors would have a reasonably foreseeable potential for clinical impact/harm, potentially resulting in direct physical injury to the user and/or conditions that require medical intervention. Safety-critical tasks included the following: release activation button; check the expiry date; inspect device prior to use; and inspect medication prior to use. Essential tasks included those essential to the execution of the injection. Essential tasks included the following: open the carton, remove the device and associated documents; remove cap; start an injection by depressing the needle-shield at the injection site and pressing the activation button; and hold the autoinjector until the complete dose has been delivered. The percentage of participants who successfully performed safety-critical and essential tasks during the first unassisted use (Day 14) was reported.

Time frame:
Day 14
Reported as:
Number · percentage of participants
Percentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During First Unassisted Use
percentage of participantsRA Group 1 (Self-Administration)CaregiversHealthcare Professionals
Open carton, remove device/documents100.00100.00100.00
Remove cap100.00100.00100.00
Start injection93.7594.12100.00
Hold until complete dose delivered100.00100.00100.00
Release activation button100.00100.00100.00
Check expiry date88.2458.8272.22
Inspect device prior to use76.4747.0666.67
Inspect medication prior to use82.3582.3588.89
PrimaryPercentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During Second Unassisted Use

Safety-critical tasks included those tasks where errors would have a reasonably foreseeable potential for clinical impact/harm, potentially resulting in direct physical injury to the user and/or conditions that require medical intervention. Safety-critical tasks included the following: release activation button; check the expiry date; inspect device prior to use; and inspect medication prior to use. Essential tasks included those essential to the execution of the injection. Essential tasks included the following: open the carton, remove the device and associated documents; remove cap; start an injection by depressing the needle-shield at the injection site and pressing the activation button; and hold the autoinjector until the complete dose has been delivered. The percentage of participants who successfully performed safety-critical and essential tasks during the second unassisted use (Day 28) was reported.

Time frame:
Day 28
Reported as:
Number · percentage of participants
Percentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During Second Unassisted Use
percentage of participantsRA Group 1 (Self-Administration)CaregiversHealthcare Professionals
Open carton, remove device/documents100.00100.00100.00
Remove cap100.00100.00100.00
Start injection100.00100.00100.00
Hold until complete dose delivered100.00100.00100.00
Release activation button100.00100.00100.00
Check expiry date94.4476.4794.44
Inspect device prior to use77.7858.8283.33
Inspect medication prior to use88.8970.5994.44
SecondaryPercentage of Participants Who Successfully Performed Ancillary Tasks During First and Second Unassisted Use

Ancillary tasks included those tasks where the potential harm resulting from use error would be minor in severity, or the resultant harms were estimated to occur at sufficiently low levels. Ancillary tasks included the following: wash hands; clean the injection site with alcohol swab; wait for the alcohol to dry; dispose of the autoinjector cap; inspect full dose delivered after use; dispose of the autoinjector; and treatment of injection site after injection. The percentage of participants who succesffully performed ancillary tasks during the first (Day 14) and second unassisted use (Day 28) was reported.

Time frame:
Days 14, 28
Reported as:
Number · percentage of participants
Percentage of Participants Who Successfully Performed Ancillary Tasks During First and Second Unassisted Use
percentage of participantsRA Group 1 (Self-Administration)CaregiversHealthcare Professionals
Day (D) 14, wash hands82.3582.3577.78
D28, wash hands88.8994.12100.00
D14, clean/swab injection site100.00100.00100.00
D28, clean/swab injection site94.44100.00100.00
D14, wait for alcohol to dry94.1294.1288.89
D28, wait for alcohol to dry82.35100.0083.33
D14, dispose of device cap94.1286.6783.33
D28, dispose of device cap94.4488.2494.44
D14, inspect full dose delivered100.00100.00100.00
D28, inspect full dose delivered94.4494.12100.00
D14, dispose of device93.33100.00100.00
D28, dispose of device94.4494.12100.00
D14, treatment of site post injection100.00100.00100.00
D28, treatment of site post injection100.00100.00100.00
SecondaryVisual Analog Scale (VAS) Score for Injection Pain Among Participants With RA

Injection pain was assessed on a continuous 100-millimeter (mm) VAS, where 0 mm represents "no pain" and 100 mm represents "unbearable pain". The mean VAS response at each assessment timepoint was reported among participants with RA.

Time frame:
0 and 15 minutes after injection on Days 0, 14, 28
Reported as:
Mean · mm
Visual Analog Scale (VAS) Score for Injection Pain Among Participants With RA
mmRA Group 1 (Self-Administration)RA Group 2 (Administration by CG)RA Group 3 (Administration by HCP)
D0, 0 minutes (min)2.8 ± 4.09.9 ± 13.713.3 ± 22.9
D0, 15min1.2 ± 2.30.9 ± 1.90.8 ± 1.9
D14, 0min5.4 ± 12.95.0 ± 7.011.4 ± 17.3
D14, 15min1.5 ± 2.80.5 ± 0.90.7 ± 1.4
D28, 0min4.5 ± 5.25.8 ± 9.014.5 ± 20.1
D28, 15min0.6 ± 1.51.9 ± 5.70.7 ± 1.2
SecondaryPercentage of Participants by Response to Categorical Scale of Injection Pain Among Participants With RA

Injection pain was assessed on a categorical 6-point Likert scale, ranging from "no pain" to "severe and intolerable". The percentage of participants was reported by response at each assessment timepoint among participants with RA.

Time frame:
0 and 15 minutes after injection on Days 0, 14, 28
Reported as:
Number · percentage of participants
Percentage of Participants by Response to Categorical Scale of Injection Pain Among Participants With RA
percentage of participantsRA Group 1 (Self-Administration)RA Group 2 (Administration by CG)RA Group 3 (Administration by HCP)
D0, 0min, no pain66.747.147.4
D0, 0min, minimal but tolerable33.341.221.1
D0, 0min, mild but tolerable011.821.1
D0, 0min, moderate but tolerable005.3
D0, 0min, moderate-severe/tolerable005.3
D0, 0min, severe and intolerable000
D0, 15min, no pain88.9100.094.7
D0, 15min, minimal but tolerable11.105.3
D0, 15min, mild but tolerable000
D0, 15min, moderate but tolerable000
D0, 15min, moderate-severe/tolerable000
D0, 15min, severe and intolerable000
D14, 0min, no pain70.664.752.9
D14, 0min, minimal but tolerable23.535.317.6
D14, 0min, mild but tolerable5.9011.8
D14, 0min, moderate but tolerable005.9
D14, 0min, moderate-severe/tolerable0011.8
D14, 0min, severe and intolerable000
D14, 15min, no pain88.2100.082.4
D14, 15min, minimal but tolerable11.8017.6
D14, 15min, mild but tolerable000
D14, 15min, moderate but tolerable000
D14, 15min, moderate-severe/tolerable000
D14, 15min, severe and intolerable000
D28, 0min, no pain72.268.855.6
D28, 0min, minimal but tolerable27.818.833.3
D28, 0min, mild but tolerable012.55.6
D28, 0min, moderate but tolerable005.6
D28, 0min, moderate-severe/tolerable000
D28, 0min, severe and intolerable000
D28, 15min, no pain100.0100.088.9
D28, 15min, minimal but tolerable0011.1
D28, 15min, mild but tolerable000
D28, 15min, moderate but tolerable000
D28, 15min, moderate-severe/tolerable000
D28, 15min, severe and intolerable000
SecondaryPercentage of Participants by Response to Device Satisfaction Questionnaire

Device satisfaction was assessed using twelve questions on a categorical 5-point Likert scale, ranging from "strongly agree" to "strongly disagree". Question (Q) 1 (felt the autoinjection was easy to use), Q2 (felt comfortable while using the autoinjector), Q3 (felt the autoinjector was easy to hold), Q4 (able to tell when injection had completed), Q5 (felt he/she can inject properly with the autoinjector), Q6 (felt he/she had control over the injection process), Q7 (felt confident that he/she injected successfully), Q8 (felt it is easy to dispose of the autoinjector), Q9 (autoinjector would help to manage his/her injection schedule), Q10 (liked the look/feel of the autoinjector), Q11 (would recommend the autoinjector to someone else who needed to inject), Q12 (would continue having injections with the autoinjector). The percentage of participants was reported by response at each assessment among participants with RA, CGs, and HCPs.

Time frame:
Days 0, 14, 28
Reported as:
Number · percentage of participants
Percentage of Participants by Response to Device Satisfaction Questionnaire
percentage of participantsRA Group 1 (Self-Administration)CaregiversHealthcare ProfessionalsRA Group 2 (Administration by CG)RA Group 3 (Administration by HCP)
Q1, D0, strongly disagree00———
Q1, D0, disagree00———
Q1, D0, neutral5.65.9———
Q1, D0, agree11.10———
Q1, D0, strongly agree83.394.1———
Q1, D14, strongly disagree11.86.30——
Q1, D14, disagree000——
Q1, D14, neutral005.3——
Q1, D14, agree11.812.536.8——
Q1, D14, strongly agree76.581.357.9——
Q1, D28, strongly disagree000——
Q1, D28, disagree011.80——
Q1, D28, neutral000——
Q1, D28, agree16.711.827.8——
Q1, D28, strongly agree83.376.572.2——
Q2, D0, strongly disagree00———
Q2, D0, disagree05.9———
Q2, D0, neutral00———
Q2, D0, agree22.211.8———
Q2, D0, strongly agree77.882.4———
Q2, D14, strongly disagree5.900——
Q2, D14, disagree06.30——
Q2, D14, neutral000——
Q2, D14, agree23.512.542.1——
Q2, D14, strongly agree70.681.357.9——
Q2, D28, strongly disagree000——
Q2, D28, disagree011.80——
Q2, D28, neutral000——
Q2, D28, agree16.711.827.8——
Q2, D28, strongly agree83.376.572.2——
Q3, D0, strongly disagree00———
Q3, D0, disagree5.60———
Q3, D0, neutral5.65.9———
Q3, D0, agree27.85.9———
Q3, D0, strongly agree61.188.2———
Q3, D14, strongly disagree5.900——
Q3, D14, disagree5.96.30——
Q3, D14, neutral06.30——
Q3, D14, agree17.618.831.6——
Q3, D14, strongly agree70.668.868.4——
Q3, D28, strongly disagree000——
Q3, D28, disagree05.90——
Q3, D28, neutral000——
Q3, D28, agree16.711.822.2——
Q3, D28, strongly agree83.382.477.8——
Q4, D0, strongly disagree00———
Q4, D0, disagree11.15.9———
Q4, D0, neutral05.9———
Q4, D0, agree44.417.6———
Q4, D0, strongly agree44.470.6———
Q4, D14, strongly disagree5.900——
Q4, D14, disagree5.96.70——
Q4, D14, neutral11.800——
Q4, D14, agree17.613.331.6——
Q4, D14, strongly agree58.880.068.4——
Q4, D28, strongly disagree05.90——
Q4, D28, disagree000——
Q4, D28, neutral000——
Q4, D28, agree22.211.816.7——
Q4, D28, strongly agree77.882.483.3——
Q5, D0, strongly disagree00———
Q5, D0, disagree00———
Q5, D0, neutral11.10———
Q5, D0, agree22.211.8———
Q5, D0, strongly agree66.788.2———
Q5, D14, strongly disagree5.900——
Q5, D14, disagree06.30——
Q5, D14, neutral5.96.30——
Q5, D14, agree11.8015.8——
Q5, D14, strongly agree76.587.584.2——
Q5, D28, strongly disagree000——
Q5, D28, disagree05.90——
Q5, D28, neutral000——
Q5, D28, agree16.711.822.2——
Q5, D28, strongly agree83.382.477.8——
Q6, D0, strongly disagree00———
Q6, D0, disagree5.60———
Q6, D0, neutral5.65.9———
Q6, D0, agree16.75.9———
Q6, D0, strongly agree72.288.2———
Q6, D14, strongly disagree5.900——
Q6, D14, disagree5.96.30——
Q6, D14, neutral06.30——
Q6, D14, agree11.812.526.3——
Q6, D14, strongly agree76.575.073.7——
Q6, D28, strongly disagree000——
Q6, D28, disagree000——
Q6, D28, neutral05.90——
Q6, D28, agree16.711.822.2——
Q6, D28, strongly agree83.382.477.8——
Q7, D0, strongly disagree00———
Q7, D0, disagree11.15.9———
Q7, D0, neutral00———
Q7, D0, agree16.717.6———
Q7, D0, strongly agree72.276.5———
Q7, D14, strongly disagree5.900——
Q7, D14, disagree000——
Q7, D14, neutral5.900——
Q7, D14, agree17.66.721.1——
Q7, D14, strongly agree70.693.378.9——
Q7, D28, strongly disagree05.90——
Q7, D28, disagree000——
Q7, D28, neutral000——
Q7, D28, agree16.711.811.1——
Q7, D28, strongly agree83.382.488.9——
Q8, D0, strongly disagree00———
Q8, D0, disagree00———
Q8, D0, neutral00———
Q8, D0, agree16.75.9———
Q8, D0, strongly agree83.394.1———
Q8, D14, strongly disagree000——
Q8, D14, disagree5.900——
Q8, D14, neutral000——
Q8, D14, agree17.6010.5——
Q8, D14, strongly agree76.5100.089.5——
Q8, D28, strongly disagree000——
Q8, D28, disagree05.90——
Q8, D28, neutral000——
Q8, D28, agree16.711.811.1——
Q8, D28, strongly agree83.382.488.9——
Q9, D0, strongly disagree0——7.10
Q9, D0, disagree0——00
Q9, D0, neutral5.6——7.117.6
Q9, D0, agree38.9——28.629.4
Q9, D0, strongly agree55.6——57.152.9
Q9, D14, strongly disagree0——00
Q9, D14, disagree (n=17,0,0,16,17)0——00
Q9, D14, neutral5.9——12.523.5
Q9, D14, agree35.3——18.823.5
Q9, D14, strongly agree58.8——68.852.9
Q9, D28, strongly disagree0——05.6
Q9, D28, disagree0——00
Q9, D28, neutral0——12.516.7
Q9, D28, agree27.8——18.833.3
Q9, D28, strongly agree72.2——68.844.4
Q10, D0, strongly disagree00—7.10
Q10, D0, disagree00—00
Q10, D0, neutral11.111.8—7.111.8
Q10, D0, agree33.311.8—21.441.2
Q10, D0, strongly agree55.676.5—64.347.1
Q10, D14, strongly disagree5.90000
Q10, D14, disagree5.9006.35.9
Q10, D14, neutral0006.311.8
Q10, D14, agree23.543.831.612.541.2
Q10, D14, strongly agree64.756.368.475.041.2
Q10, D28, strongly disagree05.9000
Q10, D28, disagree00005.6
Q10, D28, neutral11.105.612.50
Q10, D28, agree16.735.327.818.844.4
Q10, D28, strongly agree72.258.866.768.850.0
Q11, D0, strongly disagree00—14.30
Q11, D0, disagree00—00
Q11, D0, neutral05.9—7.15.9
Q11, D0, agree27.85.9—21.435.3
Q11, D0, strongly agree72.288.2—57.158.8
Q11, D14, strongly disagree5.90000
Q11, D14, disagree5.96.3000
Q11, D14, neutral0006.311.8
Q11, D14, agree11.818.821.112.535.3
Q11, D14, strongly agree76.575.078.981.352.9
Q11, D28, strongly disagree05.9000
Q11, D28, disagree05.9005.6
Q11, D28, neutral00012.55.6
Q11, D28, agree16.75.933.36.333.3
Q11, D28, strongly agree83.382.466.781.355.6
Q12, D0, strongly disagree0——14.30
Q12, D0, disagree0——00
Q12, D0, neutral5.6——05.9
Q12, D0, agree27.8——21.435.3
Q12, D0, strongly agree66.7——64.358.8
Q12, D14, strongly disagree5.9——00
Q12, D14, disagree5.9——05.9
Q12, D14, neutral0——6.35.9
Q12, D14, agree5.9——12.535.3
Q12, D14, strongly agree82.4——81.352.9
Q12, D28, strongly disagree0——00
Q12, D28, disagree0——6.35.6
Q12, D28, neutral5.6——05.6
Q12, D28, agree11.1——25.033.3
Q12, D28, strongly agree83.3——68.855.6
SecondaryTender Joint Count (TJC) Among Participants With RA

Sixty-eight joints were assessed for tenderness among participants with RA. The number of tender joints at Baseline was reported.

Time frame:
Baseline (Day 0)
Reported as:
Mean · tender joints
Tender Joint Count (TJC) Among Participants With RA
tender jointsRA Group 1 (Self-Administration)RA Group 2 (Administration by CG)RA Group 3 (Administration by HCP)
Tender Joint Count (TJC) Among Participants With RA11.17 ± 9.328.12 ± 11.2916.32 ± 16.17
SecondarySwollen Joint Count (SJC) Among Participants With RA

Sixty-six joints were assessed for swelling among participants with RA. The number of swollen joints at Baseline was reported.

Time frame:
Baseline (Day 0)
Reported as:
Mean · swollen joints
Swollen Joint Count (SJC) Among Participants With RA
swollen jointsRA Group 1 (Self-Administration)RA Group 2 (Administration by CG)RA Group 3 (Administration by HCP)
Swollen Joint Count (SJC) Among Participants With RA4.61 ± 4.103.71 ± 4.458.89 ± 7.88
SecondaryChange From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Among Participants With RA

Ability to perform daily living activities was assessed across eight component sets including dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities. Twenty questions were scored on a 4-point Likert scale from 0 meaning "without any difficulty" to 3 meaning "unable to do". The overall score was computed as the sum of domain scores divided by the number of domains answered. Therefore, the score range for HAQ-DI was the same as that of the individual questions, that is, from 0 to 3, where 0 indicates "least difficulty" and 3 indicates "extreme difficulty". The mean change from baseline in HAQ-DI at each assessment was reported among participants with RA.

Time frame:
Days 0, 14, 28
Reported as:
Mean · units on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Among Participants With RA
units on a scaleRA Group 1 (Self-Administration)RA Group 2 (Administration by CG)RA Group 3 (Administration by HCP)
D00.7222 ± 0.69740.8676 ± 0.65321.2434 ± 0.6541
Change at D140.0962 ± 0.2166-0.0368 ± 0.1863-0.0441 ± 0.2575
Change at D280.0139 ± 0.2674-0.0078 ± 0.2519-0.0903 ± 0.3398

Adverse events

Collected over Days 0-28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RA Group 1 (Self-Administration)—0/18 (0%)4/18 (22.2%)
RA Group 2 (Administration by CG)—0/17 (0%)4/17 (23.5%)
RA Group 3 (Administration by HCP)—0/19 (0%)3/19 (15.8%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventRA Group 1 (Self-Administration)RA Group 2 (Administration by CG)RA Group 3 (Administration by HCP)
Arthropod biteInjury, poisoning and procedural complications0/180/172/19
StomatitisGastrointestinal disorders0/181/170/19
Injection site pruritusGeneral disorders0/181/170/19
Upper respiratory tract infectionInfections and infestations0/181/170/19
DizzinessNervous system disorders0/181/170/19
Abdominal painGastrointestinal disorders1/180/170/19
DiarrhoeaGastrointestinal disorders1/180/170/19
VomitingGastrointestinal disorders1/180/170/19
Injection site bruisingGeneral disorders1/180/170/19
HypersensitivityImmune system disorders1/180/170/19

Baseline characteristics

Safety Population: All participants who received (or in the case of CGs and HCPs, administered) at least one dose of study drug.

Age, Categorical
Age, Categorical(Participants)CaregiversHealthcare ProfessionalsRA Group 1 (Self-Administration)RA Group 2 (Administration by CG)RA Group 3 (Administration by HCP)Total
<=18 years000000
Between 18 and 65 years151714151677
>=65 years2242313
Sex: Female, Male
Sex: Female, Male(Participants)CaregiversHealthcare ProfessionalsRA Group 1 (Self-Administration)RA Group 2 (Administration by CG)RA Group 3 (Administration by HCP)Total
Female121713131368
Male5254622
08

Study locations

8 sites
  • Arizona Arthritis and Rheuma
    Mesa, Arizona 85202, United States
  • Valerius Medical Group & Research Ctr of Greater Long Beach
    Los Alamitos, California 90720, United States
  • Pacific Arthritis Ctr Med Grp
    Santa Maria, California 93454, United States
  • Bluegrass Comm Research, Inc.
    Lexington, Kentucky 40515, United States
  • Oklahoma Center For Arthritis Therapy & Research
    Tulsa, Oklahoma 74104, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Advanced Rheumatology & Arthritis Research Center
    Wexford, Pennsylvania 15090, United States
  • Metroplex Clinical Research
    Dallas, Texas 75231, United States
09

References and documents

Publications

  • Fettner S, Mela C, Wildenhahn F, Tavanti M, Wells C, Douglass W, Mallalieu NL. Evidence of bioequivalence and positive patient user handling of a tocilizumab autoinjector. Expert Opin Drug Deliv. 2019 May;16(5):551-561. doi: 10.1080/17425247.2019.1604678. Epub 2019 May 2. PubMed 31043095 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Jul 2016, 4 months.

Results were first posted in Apr 2019, 2 years 8 months after primary completion. A results delay was requested in Jul 2017.

Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 4 months is below that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2016
First posted
Feb 15, 2016
StartActual
Mar 21, 2016
Primary completionActual
Jul 29, 2016
CompletionActual
Jul 29, 2016
Results delay requested
Jul 20, 2017
Results first posted
Apr 19, 2019
Last update
Apr 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02682823
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 15, 2016
Start date
Mar 21, 2016
Primary completion
Jul 29, 2016
Completion
Jul 29, 2016
Results posted
Apr 19, 2019
Last update
Apr 19, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion